Janssen Gets FDA Approval for Akeega for Prostate Cancer

The Janssen Pharmaceutical Companies of Johnson & Johnson says the FDA has approved Akeega for treatment of adult patients with deleterious or suspected deleterious BRCA-positive metastatic castration-resistant prostate cancer.

• Approval is based on the Phase 3 MAGNITUDE study
• In patients treated with the combination Akeega plus prednisone, a statistically significant 47% risk reduction was observed for radiographic progression-free survival

To view the source of this information, click here

To contact the reporter on this story:
Lin Cheng in New York at lcheng97@bloomberg.net

To contact the editor responsible for this story:
Sunil Kesur at skesur@bloomberg.net

© 2023 Bloomberg L.P. All rights ...